1.      PHF Science. Recommendation for Seasonal InfluenzaVaccine Composition for New Zealand for 2026. Available from: https://www.phfscience.nz/digital-library/influenza-vaccine-recommendations-report-for-2026/

2.       Chow EJ,Rolfes MA, O'Halloran A, Anderson EJ, Bennett NM, Billing L, et al. AcuteCardiovascular Events Associated With Influenza in Hospitalized Adults: ACross-sectional Study. Annals of internal medicine. 2020;173(8):605-13.

3.       Boer ARd,Riezebos-Brilman A, Hout Dv, Mourik MSMv, Rümke LW, Hoog MLAd, et al. InfluenzaInfection and Acute Myocardial Infarction. NEJM Evidence.2024;3(7):EVIDoa2300361.

4.      Muñoz-QuilesC, López-Lacort M, Urchueguía A, Díez-Domingo J, Orrico-Sánchez A. Risk ofCardiovascular Events After Influenza: A Population-Based Self-Controlled CaseSeries Study, Spain, 2011–2018. The Journal of Infectious Diseases.2024;230(3):e722-e31.

5.       DavidsonJA, Banerjee A, Douglas I, Leyrat C, Pebody R, McDonald HI, et al. Primaryprevention of acute cardiovascular events by influenza vaccination: anobservational study. European Heart Journal. 2023;44(7):610-20.

6.      FröbertO, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al.Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind,Placebo-Controlled, Multicenter Trial. Circulation. 2021;144(18):1476-84.

7.      DohertyTM, Hausdorff WP, Kristinsson KG. Effect of vaccination on the use ofantimicrobial agents: a systematic literature review. Annals of medicine.2020;52(6):283-99.

8.      MarchisioP, Esposito S, Bianchini S, Dusi E, Fusi M, Nazzari E, et al. Efficacy ofinjectable trivalent virosomal-adjuvanted inactivated influenza vaccine inpreventing acute otitis media in children with recurrent complicated ornoncomplicated acute otitis media. The Pediatric Infectious Disease Journal.2009;28(10):855-9.

9.      CheungIsabella MY, Paynter J, Broderick D, Trenholme A, Byrnes Cass A, Grant CameronC, et al. Severe Acute Respiratory Infection (SARI) due to Influenza inPost-COVID Resurgence: Disproportionate Impact on Older Māori and PacificPeoples. Influenza and Other Respiratory Viruses. 2024;18(11):e70029.

10.   WorldHealth Organization. Vaccines against influenza: WHO position paper – May 2022.Weekly Epidemiological Record. 2022;97(19):185-208.

11.    Health New Zealand. Pregnancy and ImmunisationsWellington Health New Zealand; 2025 [4 October 2025]. Available from: https://info.health.nz/immunisations/when-to-immunise/pregnancy-and-immunisations

12.    Prasad N,Huang QS, Wood T, Aminisani N, McArthur C, Baker MG, et al.Influenza-Associated Outcomes Among Pregnant, Postpartum, and Nonpregnant Womenof Reproductive Age. The Journal of Infectious Diseases. 2019;219(12):1893-903.

13.    MarshallH, McMillan M, Andrews RM, Macartney K, Edwards K. Vaccines in pregnancy: Thedual benefit for pregnant women and infants. Human vaccines &immunotherapeutics. 2016;12(4):848-56.

14.   DawoodFS, Kittikraisak W, Patel A, Rentz Hunt D, Suntarattiwong P, Wesley MG, et al.Incidence of influenza during pregnancy and association with pregnancy andperinatal outcomes in three middle-income countries: a multisite prospectivelongitudinal cohort study. The Lancet Infectious Diseases. 2021;21(1):97-106.

15.    Duque J,Howe AS, Azziz-Baumgartner E, Petousis-Harris H. Multi-decade national cohortidentifies adverse pregnancy and birth outcomes associated with acuterespiratory illness hospitalisations during the influenza season. InfluenzaOther Respir Viruses. 2023;17(1):e13063.

16.   PoehlingKA, Szilagyi PG, Staat MA, Snively BM, Payne DC, Bridges CB, et al. Impact ofmaternal immunization on influenza hospitalizations in infants. American Journalof Obstetrics and Gynecology. 2011;204(6 Suppl 1):S141-8.

17.    Cohen SA,Chui KK, Naumova EN. Influenza vaccination in young children reducesinfluenza-associated hospitalizations in older adults, 2002-2006. J Am GeriatrSoc. 2011;59(2):327-32.

18.   CaldasAfonso A, Gouveia C, Januário G, Carmo M, Lopes H, Bricout H, et al. Uncoveringthe burden of Influenza in children in Portugal, 2008-2018. BMC infectiousdiseases. 2024;24(1):100.

19.   Ruf BR,Knuf M. The burden of seasonal and pandemic influenza in infants and children.Eur J Pediatr. 2014;173(3):265-76.

20.  Somes MP,Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack rate of seasonalinfluenza among unvaccinated individuals: A systematic review andmeta-analysis. Vaccine. 2018;36(23):3199-207.

21.    Huang QS,Bandaranayake D, Wood T, Newbern EC, Seeds R, Ralston J, et al. Risk Factorsand Attack Rates of Seasonal Influenza Infection: Results of the SouthernHemisphere Influenza and Vaccine Effectiveness Research and Surveillance(SHIVERS) Seroepidemiologic Cohort Study. The Journal of Infectious Diseases.2019;219(3):347-57.

22.   WilliamsKV, Krauland MG, Nowalk MP, Harrison LH, Williams JV, Roberts MS, Zimmerman RK.Increasing child vaccination coverage can reduce influenza cases across agegroups: An agent-based modeling study. The Journal of Infection.2025;90(3):106443.

23.   HeikkinenT, Silvennoinen H, Heinonen S, Vuorinen T. Clinical and socioeconomic impact ofmoderate-to-severe versus mild influenza in children. European journal ofclinical microbiology & infectious diseases: official publication of theEuropean Society of Clinical Microbiology. 2016;35(7):1107-13.

24.   HealthNew Zealand. Flu (Influenza) vaccine. Wellington: Health New Zealand 2025 [4October 2025]. Available from: https://info.health.nz/immunisations/vaccines-aotearoa/flu-vaccine

25.   CruzetaAP, Schneider IJ, Traebert J. Impact of seasonality and annual immunization ofelderly people upon influenza-related hospitalization rates. Internationaljournal of infectious diseases: IJID: official publication of the InternationalSociety for Infectious Diseases. 2013;17(12):e1194-7.

26.  Sah P,Medlock J, Fitzpatrick MC, Singer BH, Galvani AP. Optimizing the impact oflow-efficacy influenza vaccines. Proceedings of the National Academy ofSciences of the United States of America. 2018;115(20):5151-6.

27.   Langer J,Welch VL, Moran MM, Cane A, Lopez SMC, Srivastava A, et al. High ClinicalBurden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? ASystematic Literature Review. Advances in Therapy. 2023;40(4):1601-27.

28.   GovaertTM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy ofinfluenza vaccination in elderly individuals. A randomized double-blindplacebo-controlled trial. JAMA. 1994;272(21):1661-5.

29. Ministry of Health. Tatau Kahukura:Maori HealthChart Book 2024 (4th edition) [Internet] Wellington: Ministry of Health; 2024[19 Dec 2024]. Available from: https://www.health.govt.nz/publications/tatau-kahukura-maori-health-chart-book-2024

30.  Lord O,Malone D, Mitchell AJ. Receipt of preventive medical care and medical screeningfor patients with mental illness: a comparative analysis. General HospitalPsychiatry. 2010;32(5):519-43.

31.    HassounehL, Dunsiger S. The impact of mental distress on influenza vaccine coverage.PloS one. 2022;17(4):e0266692.

32.   WHONational Influenza Centre HIT. Recommendation for seasonal influenza vaccinecomposition for New Zealand for 2026. Wellington: PHF Science/New ZealandInstitute for Public Health and Forensic Science; 2025.

33.   Medsafe.Data sheet - Fluzone Wellington: New Zealand Medicines and Medical DevicesSafety Authority. Available from: https://medsafe.govt.nz/DbSearch/InfoSearch

34.   Medsafe.Data sheet - Fluad [Internet] Wellington: New Zealand Medicines and MedicalDevices Safety Authority. Available from: https://medsafe.govt.nz/Medicines/infoSearch.asp

35.   Medsafe.Data sheet - Influvac Tetra [Internet] Wellington: New Zealand Medicines and Medical Devices Safety Authority.Available from: https://medsafe.govt.nz/Medicines/infoSearch.asp

36.  Medsafe.Data sheet - Flucelvax: Wellington: New Zealand Medicines and Medical DevicesSafety Authority. Available from: https://medsafe.govt.nz/Medicines/infoSearch.asp

37.   Boikos C,McGovern I, Molrine D, Ortiz JR, Puig-Barberà J, Haag M. Review of AnalysesEstimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent InfluenzaVaccine in Three Consecutive US Influenza Seasons. Vaccines (Basel).2022;10(6).

38.   Stein AN,Thanataveerat A, McDermott K, Dean A, Wall S, Pack C, et al. SuperiorEffectiveness and Estimated Public Health Impact of Cell-Versus Egg-BasedInfluenza Vaccines in Children and Adults During the US 2023-2024 Season.Infect Dis Ther. 2025.

39.  Ku JH,Rayens E, Sy LS, Qian L, Ackerson BK, Luo Y, et al. Comparative Effectivenessof Licensed Influenza Vaccines in Preventing Influenza-related MedicalEncounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults≥65 Years of Age. Clin Infect Dis. 2024;79(5):1283-92.

40. GoldsmithJJ, Tavlian S, Vu C, Regan AK, Gibney KB, Campbell PT, Sullivan SG. Comparisonof 2 Doses vs 1 Dose in the First Season Children Are Vaccinated AgainstInfluenza: A Systematic Review and Meta-Analysis. JAMA Network Open.2025;8(10):e2535250-e.

41.   AustralasianSociety of Clinical Immunology and Allergy. Vaccination of the egg‑allergic individual. Sydney:Australasian Society of Clinical Immunology and Allergy; 2022.

42.   AllergyASoCIa. Sulfonamide Antibiotic Allergy Frequently Asked Questions. Sydney:Australasian Society of Clinical Immunology and Allergy; 2024.

43.   Beck CR,McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS. Influenza vaccination forimmunocompromised patients: systematic review and meta-analysis by etiology.The Journal of Infectious Diseases. 2012;206(8):1250-9.

44.  Kuo AM,Brown JN, Clinard V. Effect of influenza vaccination on internationalnormalized ratio during chronic warfarin therapy. J Clin Pharm Ther.2012;37(5):505-9.

45.   JeffersonT, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccinesfor preventing influenza in healthy adults. Cochrane Database Syst Rev.2010(7):CD001269.

46.  VellozziC, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenzavaccination: the epidemiologic evidence. Clin Infect Dis. 2014;58(8):1149-55.

47.  WeidenthalerH, Vidojkovic S, Martin BK, De Moerlooze L. Real-world safety data for MVA-BN:Increased frequency of syncope following intradermal administration forimmunization against mpox disease. Vaccine. 2024;42(22):126024.

48.  PHFScience. Pertussis Report: 26 July – 22 August 2025Wellington,NZ: PHF Science; 2025. Available from: https://www.phfscience.nz/media/yefhfdel/2025-08-28-pertussis-report.pdf

49.  Dodds L,McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, MacDonald N. Impact ofinfluenza exposure on rates of hospital admissions and physician visits becauseof respiratory illness among pregnant women. CMAJ: Canadian Medical AssociationJournal = journal de l'Association medicale canadienne. 2007;176(4):463-8.

50.  Omer SB,Bednarczyk R, Madhi SA, Klugman KP. Benefits to mother and child of influenzavaccination during pregnancy. Human vaccines & immunotherapeutics.2012;8(1):130-7.

51.    VanKerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A,Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A(H1N1) infection: a global pooled analysis. PLoS medicine. 2011;8(7):e1001053.

52.   ThompsonMG, Kwong JC, Regan AK, Katz MA, Drews SJ, Azziz-Baumgartner E, et al.Influenza Vaccine Effectiveness in Preventing Influenza-associatedHospitalizations During Pregnancy: A Multi-country Retrospective Test NegativeDesign Study, 2010–2016. Clin Infect Dis. 2018;68(9):1444-53.

53.   SteinhoffMC, Omer SB, Roy E, Arifeen SE, Raqib R, Altaye M, et al. Influenzaimmunization in pregnancy antibody responses in mothers and infants. The NewEngland Journal of Medicine. 2010;362(17):1644-6.

54.   SteffenR, Chen LH, Leggat PA. Travel vaccines-priorities determined by incidence andimpact. J Travel Med. 2023;30(7).

55.   KakoullisL, Steffen R, Osterhaus A, Goeijenbier M, Rao SR, Koiso S, et al. Influenza:seasonality and travel-related considerations. J Travel Med. 2023;30(5).

56.   BrothertonJM, Delpech VC, Gilbert GL, Hatzi S, Paraskevopoulos PD, McAnulty JM. A largeoutbreak of influenza A and B on a cruise ship causing widespread morbidity.Epidemiology and infection. 2003;130(2):263-71.

57.   RogersKB, Roohi S, Uyeki TM, Montgomery D, Parker J, Fowler NH, et al.Laboratory-based respiratory virus surveillance pilot project on select cruiseships in Alaska, 2013-15. J Travel Med. 2017;24(6).

58.   Young B,Wilder-Smith A. Influenza on cruise ships. Journal of travel medicine. 2018;25.

59.   GautretP, Steffen R. Influenza vaccine for international mass gatherings. The LancetInfectious Diseases. 2016;16(9):1004.

60. GautretP, Soula G, Parola P, Brouqui P. Hajj pilgrims' knowledge about acuterespiratory infections. Emerging infectious diseases. 2009;15(11):1861-2.

61.   BalkhyHH, Memish ZA, Bafaqeer S, Almuneef MA. Influenza a common viral infectionamong Hajj pilgrims: time for routine surveillance and vaccination. J TravelMed. 2004;11(2):82-6.

62.  Browne A,Ahmad SS, Beck CR, Nguyen-Van-Tam JS. The roles of transportation andtransportation hubs in the propagation of influenza and coronaviruses: asystematic review. J Travel Med. 2016;23(1).

63.  GoeijenbierM, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus AD. Travellersand influenza: risks and prevention. J Travel Med. 2017;24(1).

64.  Deng L,Mazzocato P, Saravanos G, Leder K, Britton PN. A high proportion ofinterseasonal childhood influenza cases in 2019 were travel related. Publichealth research & practice. 2020;30(2).

65.   FujitaDM, Dos Santos Soares G, Sartori GP, Henrique da Silva Nali L. COVID-19 andInfluenza coinfection: The rise of Omicron and H3N2 in Brazil - 2022. Travelmedicine and infectious disease. 2022;46:102262.

66.  FerdinandsJM, Fry AM, Reynolds S, Petrie J, Flannery B, Jackson ML, Belongia EA.Intraseason waning of influenza vaccine protection: Evidence from the USInfluenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin InfectDis. 2017;64(5):544-50.

67.  FreedmanDO, Kotton CN. Three RSV vaccines now recommended for many older adults; whatabout travellers? J Travel Med. 2024;31(7).

‍